Gene Therapy Improves Mobility in Spinal Muscular Atrophy Children
- Okay, here's a breakdown of the data from the provided text, focusing on the key details about the gene therapy for Spinal Muscular Atrophy (SMA):
- * therapy Name: Itvisma (onasemnogene abeparvovec) * What it is: A gene therapy for Spinal Muscular Atrophy (SMA).
- In essence, the text describes a promising new gene therapy for SMA that shows potential for improving motor function even in older patients who have already begun to...
Okay, here’s a breakdown of the data from the provided text, focusing on the key details about the gene therapy for Spinal Muscular Atrophy (SMA):
Key Points:
* therapy Name: Itvisma (onasemnogene abeparvovec)
* What it is: A gene therapy for Spinal Muscular Atrophy (SMA).
* How it’s administered: A single injection directly into the cerebrospinal fluid (intracraneal). This targets the nervous system.
* Previous Use: Initially tested and used successfully in children under two years old, as it was believed to be more effective at that age.
* Recent Study: A study was conducted with 126 children and adolescents with SMA who already showed symptoms (inability to walk independently).
* 75 received the gene therapy.
* 51 received a placebo.
* Their progress was monitored for a year.
* Results: The therapy appears to:
* Slow down the loss of strength.
* Possibly recover some mobility.
* Many children were able to sit up, stand, or even climb stairs after receiving the injection.
* Advantage over Traditional Treatments: This therapy can treat patients after symptoms have developed,unlike traditional treatments.
In essence, the text describes a promising new gene therapy for SMA that shows potential for improving motor function even in older patients who have already begun to experience the effects of the disease.
Let me know if you’d like me to elaborate on any specific aspect of this information!